4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Key Highlights
- ➤$375.0 million cash, funding operating plan into second half of 2028
- ➤4FRONT-2 randomized 531 patients; topline wet AMD data expected H2 2027
- ➤4SIGHT Phase 3 DME trial initiated with 514 treatment-naïve patients
- ➤Q3 net loss $78.1 million versus $56.9 million year-over-year
- ➤Q3 R&D expenses $69.8 million, driven by wet AMD Phase 3 trials
Expert Statements
David Kirn, Co-founder, President and Chief Executive Officer of 4DMT
“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD”
David Kirn, Co-founder, President and Chief Executive Officer of 4DMT
“In addition, we initiated the global Phase 3 4SIGHT program in DME, expanding the opportunity for 4D-150 into a second multi-billion-dollar retinal disease market with significant unmet need.”
David Kirn, Co-founder, President and Chief Executive Officer of 4DMT
“We also welcomed Dr. Eric Floyd to our executive team, providing experienced leadership for our regulatory team.”
David Kirn, Co-founder, President and Chief Executive Officer of 4DMT
“We are well positioned heading into 2027, which we anticipate will be a transformative year for the Company following expected topline readouts from both 4FRONT Phase 3 trials in wet AMD.”
* Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respectively * Presented 2-year data from PRISM and SPECTRA clinical trials of 4D-150 in wet AMD and DME, highlighting durable clinical activity and favorable, predictable safety profile * Initiated 4SIGHT Global Phase 3 clinical trial of 4D-150 in DME, advancing 4D-150 into second multi-billion-dollar retinal disease market with significant unmet need * Strengthened regulatory affairs and quality teams through the hire of Eric Floyd, PhD, MBA, as Chief Regulatory & Quality Officer * $375 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q3 2026 financial results, provided operational highlights and outlined expected upcoming milestones.
Get started
Create a free account to read the full story.